7205-46-1

Basic information

• Product Name: 6-Chloro-1-Methyl-1H-iMidazo[4,5-c]pyridine
• Synonyms: 6-Chloro-1-Methyl-1H-iMidazo[4,5-c]pyridine
• CAS NO: 7205-46-1
• Molecular Formula: C₇H₆ClN₃
• Molecular Weight: 167.59564
• Mol File: 7205-46-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 331.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.43±0.1 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 4.28±0.30(Predicted)
• CAS DataBase Reference: 6-Chloro-1-Methyl-1H-iMidazo[4,5-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-1-Methyl-1H-iMidazo[4,5-c]pyridine(7205-46-1)
• EPA Substance Registry System: 6-Chloro-1-Methyl-1H-iMidazo[4,5-c]pyridine(7205-46-1)

Safety Data

• Hazardous Substances Data: 7205-46-1(Hazardous Substances Data)

Usage

General Description

6-Chloro-1-Methyl-1H-iMidazo[4,5-c]pyridine, also known as CMIP, is a chemical compound with a molecular formula C8H7ClN2. It is a chlorinated derivative of 1-methyl-1H-imidazo[4,5-c]pyridine and belongs to the class of imidazo[4,5-c]pyridines. 6-Chloro-1-Methyl-1H-iMidazo[4,5-c]pyridine is often used in pharmaceutical research and drug development due to its potential biological activities, including its role as an anticancer and antiviral agent. CMIP's structure and properties make it a valuable intermediate in the synthesis of various pharmaceutical compounds and biologically active molecules. Additionally, its heterocyclic nature and potential biological activities make it an important target in medicinal chemistry and drug discovery.

Upstream product

• 4487-56-3 2,4-dichloro-5-nitropyridine 
• 850663-54-6 4-chloro-2-hydroxy-5-nitropyridine 
• 13091-23-1 4-chloro-3-nitropyridine 
• 87034-76-2 6-chloro-N⁴-methylpyridine-3,4-diamine 
• 149-73-5 trimethyl orthoformate 
• 64-18-6 formic acid 
• 1449506-71-1 (2-chloro-5-nitro-pyridin-4-yl)-methyl-amine 
• 607373-83-1 2-chloro-4-methoxy-5-nitro-pyridine 

Downstream Products

• 1449515-01-8 2-[3-ethyl-4-(1-methyl-1H-imidazo[4,5-c]pyridin-6-ylamino)phenyl]propionitrile 
• 1449515-02-9 (2-difluoromethoxy-4-methylphenyl)-(1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amine 
• 1449515-03-0 2-[3-ethyl-4-(1-methyl-1H-imidazo[4,5-c]pyridin-6-ylamino)phenyl]-3-oxopropionitrile 
• 1449515-06-3 1-[3-ethyl-4-(1-methyl-1H-imidazo[4,5-c]pyridin-6-ylamino)phenyl]cyclopropane carbonitrile 
• 1449515-21-2 (2-ethyl-phenyl)-(1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)-amine 
• 1449515-71-2 N-(2-ethyl-4-(pyrimidin-5-yl)phenyl)-1-methyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449514-89-9 N-(2-ethyl-4-fluorophenyl)-1-methyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449514-90-2 N-(4-(4-methoxybenzyloxy)-2-methylphenyl)-1-methyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449514-92-4 4-(4-methoxybenzyl)-7-(1-methyl-1H-imidazo[4,5-c]pyridin-6-ylamino)-2H-benzo[b][1,4]oxazin-3(4H)-one 
• 1449514-93-5 4-ethyl-N,N-dimethyl-3-(1-methyl-1H-imidazo[ 4,5-c]pyridin-6-ylamino)benzamide 
• 1449514-94-6 (4-ethyl-3-(1-methyl-1H-imidazo[4,5-c]pyridin-6-ylamino)phenyl)methanol 
• 1449668-98-7 C₁₇H₁₈N₄O₂ 
• 1449664-52-1 N-(2-chloro henyl)-N,1-dimethyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449669-05-9 methyl 3-ethyl-4-(1-methyl-1H-imidazo[4,5-c]pyridin-6-ylamino)benzoate 

Relevant articles and documents

AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS

The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Wherein R1, L1, R3, R4, Cy, L2 and R5 are as defined herein. Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.